{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:11:53Z","timestamp":1792552313873,"version":"4.5.0"},"reference-count":340,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bioorg.2026.109617","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:36:21Z","timestamp":1770856581000},"page":"109617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Expanding landscape of kinase inhibitor research in 25 years (2001-2025) and advancements of next-generation kinase inhibitors"],"prefix":"10.1016","volume":"173","author":[{"given":"Debasis","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109617_bb0005","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.tem.2015.09.013","article-title":"Protein Phosphorylation: A Major Switch Mechanism for Metabolic Regulation","volume":"26","author":"Humphrey","year":"2015","journal-title":"Trends in Endocrinology & Metabolism"},{"key":"10.1016\/j.bioorg.2026.109617_bb0010","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The Protein Kinase Complement of the Human Genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109617_bb0015","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109617_bb0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejmech.2019.03.004","article-title":"Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry","volume":"170","author":"Das","year":"2019","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.109617_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107723","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update","volume":"216","author":"Roskoski","year":"2025","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.bioorg.2026.109617_bb0030","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.bioorg.2026.109617_bb0035","first-page":"1732","article-title":"Irreversible Kinase Inhibitors Targeting Cysteine Residues and their Applications in Cancer Therapy, Mini-Reviews in Medicinal","volume":"20","author":"Das","year":"2020","journal-title":"Chemistry"},{"key":"10.1016\/j.bioorg.2026.109617_bb0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2016","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.bioorg.2026.109617_bb0045","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","article-title":"Small Molecule Kinase Inhibitor Drugs (1995\u20132021): Medical Indication, Pharmacology, and Synthesis","volume":"65","author":"Ayala-Aguilera","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109617_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105011","article-title":"The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015\u20132020","volume":"113","author":"Liang","year":"2021","journal-title":"Bioorganic Chemistry"},{"key":"10.1016\/j.bioorg.2026.109617_bb0055","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.3390\/molecules28155805","article-title":"Systematic Analysis of Covalent and Allosteric Protein Kinase Inhibitors","volume":"28","author":"Xerxa","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109617_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103366","article-title":"Trends in small molecule drug properties: A developability molecule assessment perspective","volume":"27","author":"Agarwal","year":"2022","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.bioorg.2026.109617_bb0065","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1124\/dmd.123.001430","article-title":"Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities","volume":"52","author":"Latham","year":"2024","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bioorg.2026.109617_bb0070","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1002\/cmdc.202100166","article-title":"Next-Generation Kinase Inhibitors Targeting Specific Biomarkers in Non-Small Cell Lung Cancer (NSCLC): A Recent Overview","volume":"16","author":"Das","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2026.109617_bb0075","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2174\/1568026622666220801101706","article-title":"Next-generation Bruton\u2019s Tyrosine Kinase (BTK) Inhibitors PotentiallyTargeting BTK C481S Mutation- Recent Developments and Perspectives","volume":"22","author":"Das","year":"2022","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.109617_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176484","article-title":"Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors","volume":"970","author":"Hussain","year":"2024","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.bioorg.2026.109617_bb0085","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1021\/jm3003203","article-title":"Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks","volume":"55","author":"Barf","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.109617_bb0090","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1126\/science.280.5369.1614","article-title":"Inhibition of Cell Migration, Spreading, and Focal Adhesions by Tumor Suppressor PTEN","volume":"280","author":"Tamura","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109617_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"International Immunopharmacology"},{"key":"10.1016\/j.bioorg.2026.109617_bb0100","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bioorg.2026.109617_bb0105","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.1021\/jm8010299","article-title":"Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states","volume":"51","author":"Kufareva","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2026.109617_bb0110","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1021\/jm901443h","article-title":"Through the \u201cGatekeeper Door\u201d: Exploiting the Active Kinase Conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109617_bb0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1039\/C2MD20180A","article-title":"Approaches to discover non-ATP site kinase inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.bioorg.2026.109617_bb0120","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"CPD"},{"key":"10.1016\/j.bioorg.2026.109617_bb0125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.bioorg.2026.109617_bb0130","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1111\/febs.16442","article-title":"A recent update on small-molecule kinase inhibitors for targeted cancer therapy and their therapeutic insights from mass spectrometry-based proteomic analysis","volume":"290","author":"Lee","year":"2023","journal-title":"The FEBS Journal"},{"key":"10.1016\/j.bioorg.2026.109617_bb0135","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccr.2013.02.018","article-title":"Molecular Mechanism of SSR128129E, an Extracellularly Acting, Small-Molecule, Allosteric Inhibitor of FGF Receptor Signaling","volume":"23","author":"Herbert","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109617_bb0140","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion\u2013Positive Solid Tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.bioorg.2026.109617_bb0145","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1039\/D4MD00384E","article-title":"Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019\u20132024)","volume":"15","author":"Das","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109617_bb0150","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1021\/acs.jmedchem.2c00073","article-title":"Principles of Kinase Allosteric Inhibition and Pocket Validation","volume":"65","author":"Pan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109617_bb0155","doi-asserted-by":"crossref","first-page":"15448","DOI":"10.1002\/anie.202004310","article-title":"Prey for the Proteasome: Targeted Protein Degradation\u2014A Medicinal Chemist\u2019s Perspective","volume":"59","author":"Luh","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bioorg.2026.109617_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112993","article-title":"PROTACs to address the challenges facing small molecule inhibitors","volume":"210","author":"Mart\u00edn-Acosta","year":"2021","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.109617_bb0165","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bioorg.2026.109617_bb0170","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.bioorg.2026.109617_bb0175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.14694\/EdBook_AM.2014.34.177","article-title":"50 Years of Progress in the Systemic Therapy of Non\u2013Small Cell Lung Cancer","volume":"34","author":"Wakelee","year":"2014","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"10.1016\/j.bioorg.2026.109617_bb0180","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.bioorg.2026.109617_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2018.08.009","article-title":"Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics","volume":"371","author":"Mitchell","year":"2018","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.bioorg.2026.109617_bb0190","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung Cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.bioorg.2026.109617_bb0195","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.bioorg.2026.109617_bb0200","first-page":"2748","article-title":"EGFR in Cancer: Signaling Mechanisms","volume":"13","author":"Uribe","year":"2021","journal-title":"Drugs, and Acquired Resistance, Cancers"},{"key":"10.1016\/j.bioorg.2026.109617_bb0205","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1634\/theoncologist.2014-0089","article-title":"Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations","volume":"19","author":"Khozin","year":"2014","journal-title":"The Oncologist"},{"key":"10.1016\/j.bioorg.2026.109617_bb0210","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1158\/1078-0432.CCR-15-2266","article-title":"FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation\u2013Positive Non\u2013Small Cell Lung Cancer","volume":"22","author":"Kazandjian","year":"2016","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.bioorg.2026.109617_bb0215","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non\u2013Small-Cell Lung Cancer to Gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.bioorg.2026.109617_bb0220","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb0225","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.2174\/092986711795471383","article-title":"Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations","volume":"18","author":"Pallis","year":"2011","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.109617_bb0230","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618808659","article-title":"Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience","volume":"12","author":"Ricciuti","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.bioorg.2026.109617_bb0235","unstructured":"FDA, FDA approves dacomitinib for metastatic non-small cell lung cancer, (n.d.). https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-dacomitinib-metastatic-non-small-cell-lung-cancer."},{"key":"10.1016\/j.bioorg.2026.109617_bb0240","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s40265-013-0111-6","article-title":"Afatinib: First Global Approval","volume":"73","author":"Dungo","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109617_bb0245","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.neo.2017.11.001","article-title":"Navigating the \u201cNo Man\u2019s Land\u201d of TKI-Failed EGFR-Mutated Non\u2013Small Cell Lung Cancer (NSCLC): A Review","volume":"20","author":"Oronsky","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.bioorg.2026.109617_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2016.00076","article-title":"Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line","volume":"3","author":"Sullivan","year":"2017","journal-title":"Frontiers in Medicine"},{"key":"10.1016\/j.bioorg.2026.109617_bb0255","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1021\/acs.jmedchem.0c00891","article-title":"Structural Basis of AZD9291 Selectivity for EGFR T790M","volume":"63","author":"Yan","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109617_bb0260","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1021\/acsmedchemlett.2c00213","article-title":"Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)","volume":"13","author":"Heppner","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109617_bb0265","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.bioorg.2026.109617_bb0270","unstructured":"FDA, FDA approves osimertinib for first-line treatment of metastatic NSCLC with most common EGFR mutations, (n.d.). https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-osimertinib-first-line-treatment-metastatic-nsclc-most-common-egfr-mutations."},{"key":"10.1016\/j.bioorg.2026.109617_bb0275","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00044-022-02952-5","article-title":"Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations","volume":"31","author":"Wang","year":"2022","journal-title":"Med Chem Res"},{"key":"10.1016\/j.bioorg.2026.109617_bb0280","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40265-021-01533-x","article-title":"Lazertinib: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109617_bb0285","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.lungcan.2011.10.023","article-title":"Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies","volume":"76","author":"Tan","year":"2012","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.bioorg.2026.109617_bb0290","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non\u2013small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.bioorg.2026.109617_bb0295","doi-asserted-by":"crossref","first-page":"49671","DOI":"10.18632\/oncotarget.17913","article-title":"EGFR G796D mutation mediates resistance to osimertinib","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.109617_bb0300","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-20-0229","article-title":"CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19\/T790M\/C797S Mutation","volume":"19","author":"Kashima","year":"2020","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.bioorg.2026.109617_bb0305","doi-asserted-by":"crossref","first-page":"17917","DOI":"10.1021\/acs.jmedchem.5c01661","article-title":"Profiling and Optimizing Targeted Covalent Inhibitors through EGFR-Guided Studies","volume":"68","author":"Damghani","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109617_bb0310","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241280689","article-title":"BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer","volume":"16","author":"Lim","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.bioorg.2026.109617_bb0315","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1158\/1538-7445.AM2022-3346","article-title":"Abstract 3346: BBT-207, a novel, 4th generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with broad-spectrum activity to both treatment-emergent and drug-na\u00efve mutants for the treatment of NSCLC","volume":"82","author":"Jin","year":"2022","journal-title":"Cancer Research"},{"key":"10.1016\/j.bioorg.2026.109617_bb0320","doi-asserted-by":"crossref","first-page":"S1198","DOI":"10.1016\/j.annonc.2023.09.1385","article-title":"2357P TRX-221, a 4th generation, mutant-selective, and CNS-active EGFR inhibitor with robust antitumor activity in osimertinib-resistant tumor models harboring C797S mutation","volume":"34","author":"Lim","year":"2023","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb0325","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1200\/JCO.2024.42.16_suppl.2068","article-title":"Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results","volume":"42","author":"Wen","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.bioorg.2026.109617_bb0330","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-21-P02-04","article-title":"Abstract P02-04: BDTX-1535, a CNS penetrant MasterKey inhibitor of common, uncommon and resistant EGFR mutations, demonstrates in vivo efficacy and has potential to treat osimertinib-resistant NSCLC with or without brain metastases","volume":"20","author":"Lucas","year":"2021","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.bioorg.2026.109617_bb0335","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","article-title":"HER2 expression status in diverse cancers: review of results from 37,992 patients","volume":"34","author":"Yan","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.bioorg.2026.109617_bb0340","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1573408016666200228112728","article-title":"Recent progress and developments of small molecule kinase inhibitors for the treatment of breast cancer","volume":"16","author":"Das","year":"2020","journal-title":"Current Enzyme Inhibition"},{"key":"10.1016\/j.bioorg.2026.109617_bb0345","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.2165\/11538150-000000000-00000","article-title":"Triple-Negative Breast Cancer: Epidemiology and Management Options","volume":"70","author":"Dawood","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109617_bb0350","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10549-011-1702-0","article-title":"Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer","volume":"131","author":"Tamimi","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bioorg.2026.109617_bb0355","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/abt\/tby003","article-title":"Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers","volume":"1","author":"Mohan","year":"2018","journal-title":"Antibody Therapeutics"},{"key":"10.1016\/j.bioorg.2026.109617_bb0360","first-page":"665","article-title":"A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer","volume":"3","author":"Nelson","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.bioorg.2026.109617_bb0365","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10549-007-9885-0","article-title":"A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses","volume":"112","author":"Cameron","year":"2008","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.bioorg.2026.109617_bb0370","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1200\/JCO.2019.37.15_suppl.1002","article-title":"Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial","volume":"37","author":"Saura","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb0375","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejps.2017.01.021","article-title":"Discovery and development of pyrotinib: A novel irreversible EGFR\/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer","volume":"110","author":"Li","year":"2017","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.bioorg.2026.109617_bb0380","doi-asserted-by":"crossref","first-page":"e11596","DOI":"10.1200\/jco.2015.33.15_suppl.e11596","article-title":"A phase I study for tolerability, safety, and pharmacokinetics of pyrotinib, a novel irreversible HER2 and EGFR inhibitor, in Chinese patients with HER2 + metastatic breast cancer","volume":"33","author":"Xu","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb0385","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-16-1496","article-title":"Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2 + -Advanced Solid Tumors, with an Expansion Cohort in HER2 + Metastatic Breast Cancer (MBC)","volume":"23","author":"Moulder","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.bioorg.2026.109617_bb0390","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2018.05.004","article-title":"Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer","volume":"67","author":"Duchnowska","year":"2018","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.bioorg.2026.109617_bb0395","series-title":"Poster Session Abstracts, American Association for Cancer Research","article-title":"Abstract P5-20-01: Prolonged progression-free survival (PFS) in advanced HER2+ metastatic breast cancer with or without brain metastases: A pooled analysis of tucatinib phase 1b studies","author":"Hamilton","year":"2018"},{"key":"10.1016\/j.bioorg.2026.109617_bb0400","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1470-2045(18)30256-0","article-title":"Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study","volume":"19","author":"Murthy","year":"2018","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb0405","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin\u2019s Lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109617_bb0410","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/s41388-023-02712-8","article-title":"New perspectives for targeting therapy in ALK-positive human cancers","volume":"42","author":"Zhao","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.109617_bb0415","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1158\/1078-0432.CCR-08-2762","article-title":"Inhibition of ALK Signaling for Cancer Therapy","volume":"15","author":"Mosse","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.bioorg.2026.109617_bb0420","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109617_bb0425","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.2012.44.5353","article-title":"ALK in lung cancer: past, present, and future","volume":"31","author":"Shaw","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109617_bb0430","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12943-018-0776-2","article-title":"Role and targeting of anaplastic lymphoma kinase in cancer","volume":"17","author":"Della Corte","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bioorg.2026.109617_bb0435","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal\u2013Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.109617_bb0440","series-title":"Annual Reports in Medicinal Chemistry","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/B978-0-12-417150-3.00025-9","article-title":"Case History","author":"Cui","year":"2013"},{"key":"10.1016\/j.bioorg.2026.109617_bb0445","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.lungcan.2014.02.001","article-title":"Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4\/ALK translocation","volume":"84","author":"Perez","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bioorg.2026.109617_bb0450","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109617_bb0455","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/0008-5472.CAN-11-1340","article-title":"A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors","volume":"71","author":"Sasaki","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109617_bb0460","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/JTO.0b013e318283dcc0","article-title":"Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer","volume":"8","author":"Kim","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bioorg.2026.109617_bb0465","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2012.45.2029","article-title":"Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer","volume":"31","author":"Gainor","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109617_bb0470","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1021\/acsmedchemlett.2c00514","article-title":"Addressing the Osimertinib Resistance Mutation EGFR-L858R\/C797S with Reversible Aminopyrimidines","volume":"14","author":"Grabe","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109617_bb0475","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1021\/acs.jmedchem.6b00306","article-title":"Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase","volume":"59","author":"Huang","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.109617_bb0480","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1158\/1535-7163.MCT-21-0221","article-title":"TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations","volume":"20","author":"Murray","year":"2021","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.bioorg.2026.109617_bb0485","first-page":"2367","article-title":"NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations, Cancer","volume":"14","author":"Lin","year":"2024","journal-title":"Discovery"},{"key":"10.1016\/j.bioorg.2026.109617_bb0490","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/jm400402q","volume":"56","author":"Marsilje","year":"2013","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.109617_bb0495","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.bmc.2011.12.021","article-title":"Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)","volume":"20","author":"Kinoshita","year":"2012","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.109617_bb0500","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ccr.2011.04.004","article-title":"CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant","volume":"19","author":"Sakamoto","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109617_bb0505","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bioorg.2026.109617_bb0510","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/JTO.0000000000000094","article-title":"Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802\/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib","volume":"9","author":"Ou","year":"2014","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb0515","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.21037\/cco.2018.10.12","article-title":"Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC","volume":"8","author":"Li","year":"2019","journal-title":"Chinese Clinical Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb0520","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1158\/1078-0432.CCR-17-2398","article-title":"Ensartinib (X-396) in ALK-Positive Non\u2013Small Cell Lung Cancer: Results from a First-in-Human Phase I\/II, Multicenter Study","volume":"24","author":"Horn","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bioorg.2026.109617_bb0525","first-page":"45","article-title":"Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial, The Lancet","volume":"8","author":"Yang","year":"2020","journal-title":"Respiratory Medicine"},{"key":"10.1016\/j.bioorg.2026.109617_bb0530","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"Johnson","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.109617_bb0535","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","article-title":"PF-06463922, an ALK\/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models","volume":"28","author":"Zou","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109617_bb0540","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.bioorg.2026.109617_bb0545","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/cncy.22350","article-title":"Neurotrophic receptor tyrosine kinase ( NTRK ) fusions and their role in cancer","volume":"128","author":"Ruiz-Cordero","year":"2020","journal-title":"Cancer Cytopathology"},{"key":"10.1016\/j.bioorg.2026.109617_bb0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14737140.2019.1538796","article-title":"Larotrectinib for the treatment of TRK fusion solid tumors","volume":"19","author":"Laetsch","year":"2019","journal-title":"Expert Review of Anticancer Therapy"},{"key":"10.1016\/j.bioorg.2026.109617_bb0555","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/1535-7163.MCT-15-0758","article-title":"Entrectinib, a Pan\u2013TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications","volume":"15","author":"Ardini","year":"2016","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.bioorg.2026.109617_bb0560","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40265-019-01177-y","article-title":"Entrectinib: First Global Approval","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109617_bb0565","first-page":"1227","article-title":"Repotrectinib (TPX-0005) Is a Next-Generation ROS1\/TRK\/ALK Inhibitor That Potently Inhibits ROS1\/TRK\/ALK Solvent- Front Mutations, Cancer","volume":"8","author":"Drilon","year":"2018","journal-title":"Discovery"},{"key":"10.1016\/j.bioorg.2026.109617_bb0570","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 Fusion\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bioorg.2026.109617_bb0575","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1158\/1078-0432.CCR-24-0949","article-title":"FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer","volume":"30","author":"Barbato","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bioorg.2026.109617_bb0580","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1038\/s41467-019-11496-z","article-title":"The new-generation selective ROS1\/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models","volume":"10","author":"Katayama","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.bioorg.2026.109617_bb0585","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nrclinonc.2017.188","article-title":"Erratum: Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bioorg.2026.109617_bb0590","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1089\/thy.2013.0137","article-title":"In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer","volume":"23","author":"Bentzien","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.bioorg.2026.109617_bb0595","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of Selpercatinib in RET Fusion\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bioorg.2026.109617_bb0600","doi-asserted-by":"crossref","first-page":"S1778","DOI":"10.1016\/j.jtho.2017.09.399","article-title":"OA 12.07 LOXO-292, a Potent, Highly Selective RET Inhibitor, in MKI-Resistant RET Fusion-Positive Lung Cancer Patients with and without Brain Metastases","volume":"12","author":"Velcheti","year":"2017","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb0605","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2020.38.15_suppl.3584","article-title":"Selpercatinib (LOXO-292) in patients with RET- fusion+ non-small cell lung cancer","volume":"38","author":"Goto","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb0610","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1200\/JCO.2019.37.15_suppl.9008","article-title":"Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC)","volume":"37","author":"Gainor","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb0615","unstructured":"FDA approves pralsetinib for lung cancer with RET gene fusions, (n.d.). https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions."},{"key":"10.1016\/j.bioorg.2026.109617_bb0620","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb0625","first-page":"1091","article-title":"Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer","volume":"13","author":"Fancelli","year":"2021","journal-title":"Updated Evidence and Future Perspectives, Cancers"},{"key":"10.1016\/j.bioorg.2026.109617_bb0630","doi-asserted-by":"crossref","first-page":"19536","DOI":"10.1021\/acs.jmedchem.5c01777","article-title":"Discovery of APS03118, a Potent and Selective Next-Generation RET Inhibitor with a Novel Kinase Hinge Scaffold","volume":"68","author":"Zhong","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109617_bb0635","doi-asserted-by":"crossref","first-page":"8598","DOI":"10.1200\/JCO.2025.43.16_suppl.8598","article-title":"Final results of a phase 1 study of EP0031, a next generation selective RET inhibitor (SRI) in patients with SRI na\u00efve or pretreated advanced RET-altered tumors","volume":"43","author":"Alonso","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.bioorg.2026.109617_bb0640","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s43018-023-00630-y","article-title":"Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations","volume":"4","author":"Miyazaki","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.bioorg.2026.109617_bb0645","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1158\/1078-0432.CCR-18-2814","article-title":"Capmatinib (INC280) Is Active Against Models of Non\u2013Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation","volume":"25","author":"Baltschukat","year":"2019","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.bioorg.2026.109617_bb0650","unstructured":"FDA Approved: TABRECTA, (n.d.). https:\/\/www.us.tabrecta.com\/met-exon-14-skipping-mutation-nsclc\/."},{"key":"10.1016\/j.bioorg.2026.109617_bb0655","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.860985","article-title":"Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review","volume":"10","author":"Zheng","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.bioorg.2026.109617_bb0660","first-page":"215","article-title":"The Fibroblast Growth Factor signaling pathway, WIREs","volume":"4","author":"Ornitz","year":"2015","journal-title":"Developmental Biology"},{"key":"10.1016\/j.bioorg.2026.109617_bb0665","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bioorg.2026.109617_bb0670","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1021\/jm900431g","article-title":"Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120)","volume":"52","author":"Roth","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109617_bb0675","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1021\/jm501562a","article-title":"Nintedanib: From Discovery to the Clinic","volume":"58","author":"Roth","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109617_bb0680","doi-asserted-by":"crossref","first-page":"10666","DOI":"10.1021\/acs.jmedchem.1c00713","article-title":"Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor","volume":"64","author":"Wu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109617_bb0685","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.annonc.2024.12.011","article-title":"A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma","volume":"36","author":"Goyal","year":"2025","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb0690","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.bioorg.2026.109617_bb0695","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109617_bb0700","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/13543784.2021.1864320","article-title":"Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma","volume":"30","author":"Botrus","year":"2021","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.bioorg.2026.109617_bb0705","article-title":"INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.109617_bb0710","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394.031","article-title":"FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)","volume":"30","author":"Vogel","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb0715","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1021\/acsmedchemlett.3c00006","article-title":"Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use","volume":"14","author":"Ito","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109617_bb0720","unstructured":"FDA Grants Accelerated Approval to Futibatinib for Cholangiocarcinoma, (n.d.). https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-futibatinib-cholangiocarcinoma."},{"key":"10.1016\/j.bioorg.2026.109617_bb0725","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bioorg.2026.109617_bb0730","article-title":"The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy","volume":"83","author":"Muz","year":"2015","journal-title":"HP"},{"key":"10.1016\/j.bioorg.2026.109617_bb0735","doi-asserted-by":"crossref","first-page":"10797","DOI":"10.1021\/jm301085w","article-title":"Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors","volume":"55","author":"Musumeci","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.109617_bb0740","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12935-020-01719-5","article-title":"The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment","volume":"21","author":"Emami Nejad","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.bioorg.2026.109617_bb0745","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11912-011-0154-3","article-title":"Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status","volume":"13","author":"Bhargava","year":"2011","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.bioorg.2026.109617_bb0750","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF\/MEK\/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.bioorg.2026.109617_bb0755","doi-asserted-by":"crossref","first-page":"LBA4510","DOI":"10.1200\/jco.2005.23.16_suppl.lba4510","article-title":"Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43\u20139006) in patients with advanced renal cell carcinoma (RCC)","volume":"23","author":"Escudier","year":"2005","journal-title":"JCO"},{"key":"10.1016\/j.bioorg.2026.109617_bb0760","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bioorg.2026.109617_bb0765","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14737140.2019.1559058","article-title":"Sorafenib: key lessons from over 10 years of experience","volume":"19","author":"Escudier","year":"2019","journal-title":"Expert Review of Anticancer Therapy"},{"key":"10.1016\/j.bioorg.2026.109617_bb0770","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1021\/jm0204183","volume":"46","author":"Sun","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109617_bb0775","first-page":"16","article-title":"Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor","volume":"24","author":"Motzer","year":"2006","journal-title":"Patients With Metastatic Renal Cell Carcinoma, JCO"},{"key":"10.1016\/j.bioorg.2026.109617_bb0780","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2045-824X-6-12","article-title":"Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells","volume":"6","author":"Chinchar","year":"2014","journal-title":"Vascular Cell"},{"key":"10.1016\/j.bioorg.2026.109617_bb0785","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-166","article-title":"Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study","volume":"14","author":"Bachelot","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2026.109617_bb0790","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10456-015-9476-3","article-title":"Combining radiotherapy with sunitinib: lessons (to be) learned","volume":"18","author":"Kleibeuker","year":"2015","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bioorg.2026.109617_bb0795","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11912-007-0007-2","article-title":"Pazopanib: a novel multitargeted tyrosine kinase inhibitor","volume":"9","author":"Sonpavde","year":"2007","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.bioorg.2026.109617_bb0800","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","article-title":"A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: Final overall survival results and safety update","volume":"49","author":"Sternberg","year":"2013","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.bioorg.2026.109617_bb0805","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10549-012-2369-x","article-title":"A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer","volume":"137","author":"Cristofanilli","year":"2013","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.bioorg.2026.109617_bb0810","first-page":"4645","article-title":"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration","volume":"62","author":"Wedge","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109617_bb0815","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijrobp.2005.05.050","article-title":"ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy","volume":"64","author":"Frederick","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bioorg.2026.109617_bb0820","first-page":"134","article-title":"Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized","volume":"30","author":"Wells","year":"2012","journal-title":"Double-Blind Phase III Trial, JCO"},{"key":"10.1016\/j.bioorg.2026.109617_bb0825","doi-asserted-by":"crossref","first-page":"9921","DOI":"10.1158\/0008-5472.CAN-07-1066","article-title":"The Addition of AG-013736 to Fractionated Radiation Improves Tumor Response without Functionally Normalizing the Tumor Vasculature","volume":"67","author":"Fenton","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/j.bioorg.2026.109617_bb0830","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","article-title":"Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3","volume":"14","author":"Hu-Lowe","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.bioorg.2026.109617_bb0835","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1586\/era.10.134","article-title":"Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?","volume":"10","author":"Goldstein","year":"2010","journal-title":"Expert Review of Anticancer Therapy"},{"key":"10.1016\/j.bioorg.2026.109617_bb0840","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1177\/1060028013509792","article-title":"Regorafenib: A Novel Multitargeted Tyrosine Kinase Inhibitor for Colorectal Cancer and Gastrointestinal Stromal Tumors","volume":"47","author":"Crona","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.bioorg.2026.109617_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101993","article-title":"Evolving role of regorafenib for the treatment of advanced cancers","volume":"86","author":"Grothey","year":"2020","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.bioorg.2026.109617_bb0850","first-page":"664","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition, Intl Journal of","volume":"122","author":"Matsui","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2026.109617_bb0855","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.2217\/fon-2017-0689","article-title":"Lenvatinib and its Use in the Treatment of Unresectable Hepatocellular Carcinoma","volume":"14","author":"Baxter","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.bioorg.2026.109617_bb0860","doi-asserted-by":"crossref","first-page":"9134","DOI":"10.1158\/0008-5472.CAN-05-4290","article-title":"KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties","volume":"66","author":"Nakamura","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.bioorg.2026.109617_bb0865","first-page":"441","volume":"28","author":"Chang","year":"2022","journal-title":"FDA Approval Summary"},{"key":"10.1016\/j.bioorg.2026.109617_bb0870","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.4161\/15384047.2014.964087","article-title":"Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy","volume":"15","author":"Sun","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.bioorg.2026.109617_bb0875","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12916-023-02841-7","article-title":"Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study","volume":"21","author":"Li","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.bioorg.2026.109617_bb0880","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40265-018-0939-x","article-title":"Anlotinib: First Global Approval","volume":"78","author":"Syed","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109617_bb0885","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ijbiomac.2022.01.113","article-title":"Targeting the PDGF\/PDGFR signaling pathway for cancer therapy: A review","volume":"202","author":"Zou","year":"2022","journal-title":"International Journal of Biological Macromolecules"},{"key":"10.1016\/j.bioorg.2026.109617_bb0890","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103989","article-title":"Current status of drugs targeting PDGF\/PDGFR","volume":"29","author":"Ai","year":"2024","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.bioorg.2026.109617_bb0895","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bioorg.2026.109617_bb0900","first-page":"3128","article-title":"Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized","volume":"39","author":"Kang","year":"2021","journal-title":"Open-Label Phase III Study, JCO"},{"key":"10.1016\/j.bioorg.2026.109617_bb0905","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s12885-021-08013-1","article-title":"Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data","volume":"21","author":"Von Mehren","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2026.109617_bb0910","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","article-title":"Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants","volume":"35","author":"Smith","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109617_bb0915","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bioorg.2026.109617_bb0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104367","article-title":"Targeting FLT3 for treating diseases: FLT3 inhibitors","volume":"30","author":"Rong","year":"2025","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.bioorg.2026.109617_bb0925","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1158\/1535-7163.MCT-21-0361","article-title":"Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages","volume":"20","author":"Smith","year":"2021","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.bioorg.2026.109617_bb0930","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bioorg.2026.109617_bb0935","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107505","article-title":"A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed\/refractory acute myeloid leukemia","volume":"141","author":"Mohebbi","year":"2024","journal-title":"Leukemia Research"},{"key":"10.1016\/j.bioorg.2026.109617_bb0940","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.18632\/oncotarget.27222","article-title":"Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells","volume":"10","author":"Kawase","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.109617_bb0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106808","article-title":"Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions","volume":"114","author":"Nuho\u011flu Kantarc\u0131","year":"2022","journal-title":"Leukemia Research"},{"key":"10.1016\/j.bioorg.2026.109617_bb0950","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1080\/14656566.2020.1801637","article-title":"Quizartinib for the treatment of acute myeloid leukemia","volume":"21","author":"Garcia-Horton","year":"2020","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.bioorg.2026.109617_bb0955","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2147\/DDDT.S198950","article-title":"Quizartinib (AC220): a promising option for acute myeloid leukemia","volume":"13","author":"Zhou","year":"2019","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1016\/j.bioorg.2026.109617_bb0960","unstructured":"VANFLYTA\u00ae First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML, (n.d.). https:\/\/www.biospace.com\/vanflyta-first-flt3-inhibitor-approved-in-the-u-s-specifically-for-patients-with-newly-diagnosed-flt3-itd-positive-aml."},{"key":"10.1016\/j.bioorg.2026.109617_bb0965","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2147\/DDDT.S253232","article-title":"Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development","volume":"14","author":"Benner","year":"2020","journal-title":"DDDT"},{"key":"10.1016\/j.bioorg.2026.109617_bb0970","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","article-title":"Pexidartinib: First Approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109617_bb0975","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.bioorg.2026.109617_bb0980","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128928","article-title":"Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)","volume":"74","author":"Caldwell","year":"2022","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.bioorg.2026.109617_bb0985","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.3390\/cancers16152754","article-title":"Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance","volume":"16","author":"Eshaq","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.109617_bb0990","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"American J Hematol"},{"key":"10.1016\/j.bioorg.2026.109617_bb0995","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109617_bb1000","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"Capdeville","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bioorg.2026.109617_bb1005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl -positive leukaemia","volume":"2","author":"Hoelbl","year":"2010","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.bioorg.2026.109617_bb1010","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.bioorg.2026.109617_bb1015","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Research"},{"key":"10.1016\/j.bioorg.2026.109617_bb1020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109617_bb1025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-3-47","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","volume":"3","author":"Wei","year":"2010","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bioorg.2026.109617_bb1030","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N -(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src\/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.109617_bb1035","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2147\/DDDT.S80207","article-title":"The role of dasatinib in the management of chronic myeloid leukemia","author":"Chen","year":"2015","journal-title":"DDDT"},{"key":"10.1016\/j.bioorg.2026.109617_bb1040","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bioorg.2026.109617_bb1045","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bioorg.2026.109617_bb1050","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2217\/fon-2018-0468","article-title":"Nilotinib in the Treatment of Chronic Myeloid Leukemia","volume":"15","author":"Sacha","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.bioorg.2026.109617_bb1055","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1007\/s00277-024-05851-4","article-title":"Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia","volume":"103","author":"Lipton","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bioorg.2026.109617_bb1060","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","article-title":"Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells","volume":"23","author":"Remsing Rix","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.109617_bb1065","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109617_bb1070","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.3324\/haematol.2015.132845","article-title":"Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor","volume":"100","author":"Sanford","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.bioorg.2026.109617_bb1075","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109617_bb1080","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109617_bb1085","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk Res"},{"key":"10.1016\/j.bioorg.2026.109617_bb1090","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"R\u00e9a","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109617_bb1095","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101244","article-title":"FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia","volume":"15","author":"Fang","year":"2022","journal-title":"Transl Oncol"},{"key":"10.1016\/j.bioorg.2026.109617_bb1100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1158\/1078-0432.CCR-20-1600","article-title":"Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study","volume":"27","author":"Zhang","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.bioorg.2026.109617_bb1105","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bioorg.2026.109617_bb1110","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40265-018-0927-1","article-title":"Fostamatinib: First Global Approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109617_bb1115","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol"},{"key":"10.1016\/j.bioorg.2026.109617_bb1120","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK\u2013STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109617_bb1125","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chemical Biology"},{"key":"10.1016\/j.bioorg.2026.109617_bb1130","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109617_bb1135","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109617_bb1140","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood.V110.11.556.556","article-title":"Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera","volume":"110","author":"Wernig","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109617_bb1145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.109617_bb1150","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1021\/acs.jmedchem.0c01952","article-title":"Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof","volume":"64","author":"Davis","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2026.109617_bb1155","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bioorg.2026.109617_bb1160","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109617_bb1165","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/j.bioorg.2026.109617_bb1170","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1021\/jm1004286","article-title":"Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection","volume":"53","author":"Flanagan","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109617_bb1175","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.NAJ.0000559803.24361.5e","article-title":"Tofacitinib Trial Prompts FDA Review of Adverse Effects","volume":"119","author":"Aschenbrenner","year":"2019","journal-title":"AJN, American Journal of Nursing"},{"key":"10.1016\/j.bioorg.2026.109617_bb1180","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bioorg.2026.109617_bb1185","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40265-017-0723-3","article-title":"Baricitinib: First Global Approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109617_bb1190","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.bioorg.2026.109617_bb1195","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.bioorg.2026.109617_bb1200","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cts.13146","article-title":"Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients \u2013 Analyses of phase III clinical trials","volume":"15","author":"Muensterman","year":"2022","journal-title":"Clinical Translational Sci"},{"key":"10.1016\/j.bioorg.2026.109617_bb1205","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2023.100161","article-title":"Unveiling abrocitinib: A thorough examination of the 2022 USFDA-approved treatment for atopic dermatitis (AD)","volume":"20","author":"Grajales","year":"2023","journal-title":"Medicine in Drug Discovery"},{"key":"10.1016\/j.bioorg.2026.109617_bb1210","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jaad.2022.03.045","article-title":"Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata","volume":"87","author":"King","year":"2022","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.bioorg.2026.109617_bb1215","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","article-title":"Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S, 5 R)-5-((7H -Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans","volume":"60","author":"Thorarensen","year":"2017","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.109617_bb1220","doi-asserted-by":"crossref","first-page":"AB12","DOI":"10.1016\/j.jaad.2019.06.083","article-title":"A selective inhibitor of TYK2, BMS-986165, improves molecular, cellular, and clinical biomarkers associated with efficacy in moderate-to-severe psoriasis","volume":"81","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.bioorg.2026.109617_bb1225","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bioorg.2026.109617_bb1230","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/jop.2013.0197","article-title":"Emerging Trabecular Outflow Drugs","volume":"30","author":"Kopczynski","year":"2014","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"key":"10.1016\/j.bioorg.2026.109617_bb1235","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s40265-014-0333-2","article-title":"Ripasudil: First Global Approval","volume":"74","author":"Garnock-Jones","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109617_bb1240","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/j.bmcl.2016.03.104","article-title":"Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma","volume":"26","author":"Sturdivant","year":"2016","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.bioorg.2026.109617_bb1245","doi-asserted-by":"crossref","DOI":"10.1016\/j.retram.2022.103343","article-title":"Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease","volume":"70","author":"Ali","year":"2022","journal-title":"Current Research in Translational Medicine"},{"key":"10.1016\/j.bioorg.2026.109617_bb1250","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.20.02754","article-title":"ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease","volume":"39","author":"Jagasia","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.bioorg.2026.109617_bb1255","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton\u2019s tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.bioorg.2026.109617_bb1260","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bioorg.2026.109617_bb1265","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.3390\/molecules26164907","article-title":"Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases","volume":"26","author":"Zhang","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109617_bb1270","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1134\/S1068162022010046","article-title":"Design, Synthesis of New Pyrazolo[3,4-d]Pyrimidine Derivatives and In Vitro Evaluation of Antiproliferative Activity against Leukemia Cell Lines, Russian Journal of","volume":"48","author":"Das","year":"2022","journal-title":"Bioorganic Chemistry"},{"key":"10.1016\/j.bioorg.2026.109617_bb1275","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1021\/acsmedchemlett.5c00098","article-title":"Discovery of Reversible, Noncovalent Bruton\u2019s Tyrosine Kinase Inhibitors Targeting BTK C481S Mutation","volume":"16","author":"Das","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109617_bb1280","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2217\/fon.14.51","article-title":"Ibrutinib: a first in class covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"10","author":"Davids","year":"2014","journal-title":"Future Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb1285","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in Previously Treated Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.bioorg.2026.109617_bb1290","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/mol.116.107037","article-title":"Ability of Bruton\u2019s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling","volume":"91","author":"Bender","year":"2017","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.bioorg.2026.109617_bb1295","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib: a highly selective, non-covalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109617_bb1300","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41571-024-00956-1","article-title":"Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia","volume":"21","author":"Stanchina","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bioorg.2026.109617_bb1305","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.18418","article-title":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"200","author":"Nakhoda","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bioorg.2026.109617_bb1310","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2019-127260","article-title":"Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109617_bb1315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181782","article-title":"Bruton\u2019s tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care","volume":"12","author":"Gillooly","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.bioorg.2026.109617_bb1320","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1021\/acs.jmedchem.3c01007","article-title":"Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton\u2019s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies","volume":"67","author":"Robbins","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109617_bb1325","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2023-179872","article-title":"A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton\u2019s Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed\/Refractory B Cell Malignancies","volume":"142","author":"Danilov","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109617_bb1330","article-title":"P1219: BGB-16673, A BTK DEGRADER, OVERCOMES ON-TARGET RESISTANCE FROM BTK INHIBITORS AND PRESENTS SUSTAINABLE LONG-TERM TUMOR REGRESSION IN LYMPHOMA XENOGRAFT MODELS","volume":"7","author":"Wang","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.bioorg.2026.109617_bb1335","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1182\/blood-2024-199154","article-title":"Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R\/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study","volume":"144","author":"Tam","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109617_bb1340","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12272-025-01546-0","article-title":"BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies","volume":"48","author":"Kim","year":"2025","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bioorg.2026.109617_bb1345","article-title":"Phase I\/IIa clinical study of 4th generation BTK inhibitor HBW-3220 capsules in patients with B-cell malignancies","volume":"43","author":"Lee","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.bioorg.2026.109617_bb1350","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/med.22084","article-title":"Advances in reversible covalent kinase inhibitors","volume":"45","author":"Zhao","year":"2025","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.bioorg.2026.109617_bb1355","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1021\/acs.jmedchem.1c01170","article-title":"Discovery of Reversible Covalent Bruton\u2019s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)","volume":"65","author":"Owens","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109617_bb1360","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.3390\/ijms23126381","article-title":"The Development of FAK Inhibitors: A Five-Year Update","volume":"23","author":"Spallarossa","year":"2022","journal-title":"IJMS"},{"key":"10.1016\/j.bioorg.2026.109617_bb1365","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","article-title":"Targeting FAK in anticancer combination therapies","volume":"21","author":"Dawson","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bioorg.2026.109617_bb1370","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1038\/s41591-025-03763-y","article-title":"Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial","volume":"31","author":"Banerjee","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.bioorg.2026.109617_bb1375","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2019.10.033","article-title":"Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer","volume":"139","author":"Gerber","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bioorg.2026.109617_bb1380","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.bioorg.2026.109617_bb1385","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrd3847","article-title":"Vemurafenib: the first drug approved for BRAF-mutant cancer","volume":"11","author":"Bollag","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bioorg.2026.109617_bb1390","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1124\/jpet.118.253708","article-title":"Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases","volume":"368","author":"Gampa","year":"2019","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.bioorg.2026.109617_bb1395","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.18632\/oncotarget.27775","article-title":"Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma","volume":"11","author":"Suzuki","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.109617_bb1400","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3390\/molecules22101551","article-title":"Current Development Status of MEK Inhibitors","volume":"22","author":"Cheng","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109617_bb1405","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1517\/14656566.2013.770475","article-title":"Trametinib (GSK1120212) in the treatment of melanoma","volume":"14","author":"Salama","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bioorg.2026.109617_bb1410","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","article-title":"GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition","volume":"17","author":"Gilmartin","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bioorg.2026.109617_bb1415","unstructured":"FDA approves dabrafenib plus trametinib for anaplastic thyroid cancer with BRAF V600E mutation, (n.d.). https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-dabrafenib-plus-trametinib-anaplastic-thyroid-cancer-braf-v600e-mutation."},{"key":"10.1016\/j.bioorg.2026.109617_bb1420","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107207118","article-title":"Allosteric MEK inhibitors act on BRAF\/MEK complexes to block MEK activation","volume":"118","author":"Gonzalez-Del Pino","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bioorg.2026.109617_bb1425","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40265-018-0963-x","article-title":"Encorafenib and Binimetinib: First Global Approvals","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109617_bb1430","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/17460441.2020.1746265","article-title":"The discovery and development of binimetinib for the treatment of melanoma","volume":"15","author":"Tran","year":"2020","journal-title":"Expert Opinion on Drug Discovery"},{"key":"10.1016\/j.bioorg.2026.109617_bb1435","unstructured":"FDA approves selumetinib for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas, (n.d.). https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selumetinib-neurofibromatosis-type-1-symptomatic-inoperable-plexiform-neurofibromas."},{"key":"10.1016\/j.bioorg.2026.109617_bb1440","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jamaoncol.2016.0891","article-title":"Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors","volume":"2","author":"Millis","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bioorg.2026.109617_bb1445","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.breast.2022.03.018","article-title":"The emerging role of capivasertib in breast cancer","volume":"63","author":"Andrikopoulou","year":"2022","journal-title":"The Breast"},{"key":"10.1016\/j.bioorg.2026.109617_bb1450","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR Signaling in Growth Control and Disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109617_bb1455","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112820","article-title":"Research progress of mTOR inhibitors","volume":"208","author":"Chen","year":"2020","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.109617_bb1460","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"The Lancet"},{"key":"10.1016\/j.bioorg.2026.109617_bb1465","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/nyas.12122","article-title":"Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases","volume":"1291","author":"Lebwohl","year":"2013","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.bioorg.2026.109617_bb1470","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.2011.35.6329","article-title":"Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas","volume":"30","author":"Chawla","year":"2012","journal-title":"JCO"},{"key":"10.1016\/j.bioorg.2026.109617_bb1475","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1200\/JCO.2012.45.5766","article-title":"Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy","volume":"31","author":"Demetri","year":"2013","journal-title":"JCO"},{"key":"10.1016\/j.bioorg.2026.109617_bb1480","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1200\/JCO.2016.69.0032","article-title":"Cell-Cycle Therapeutics Come of Age","volume":"35","author":"Ingham","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb1485","doi-asserted-by":"crossref","DOI":"10.1016\/j.clbc.2019.05.019","article-title":"Cyclin-Dependent Kinase 4\/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer","author":"Rossi","year":"2019","journal-title":"Clinical Breast Cancer"},{"key":"10.1016\/j.bioorg.2026.109617_bb1490","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1634\/theoncologist.2014-0443","article-title":"The Role of CDK4\/6 Inhibition in Breast Cancer","volume":"20","author":"Murphy","year":"2015","journal-title":"The Oncologist"},{"key":"10.1016\/j.bioorg.2026.109617_bb1495","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.bioorg.2026.109617_bb1500","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/CAD.0000000000000249","article-title":"CDK4\/6 inhibitors in breast cancer","volume":"26","author":"Dukelow","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.bioorg.2026.109617_bb1505","first-page":"39","article-title":"The Strange Case of CDK4\/6 Inhibitors: Mechanisms","volume":"3","author":"Knudsen","year":"2017","journal-title":"Resistance, and Combination Strategies, Trends in Cancer"},{"key":"10.1016\/j.bioorg.2026.109617_bb1510","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb1515","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s10147-018-1353-9","article-title":"Palbociclib in combination with letrozole in patients with estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients","volume":"24","author":"Mukai","year":"2019","journal-title":"International Journal of Clinical Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb1520","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1634\/theoncologist.2016-0097","article-title":"Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive\/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)","volume":"21","author":"Verma","year":"2016","journal-title":"The Oncologist"},{"key":"10.1016\/j.bioorg.2026.109617_bb1525","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.bioorg.2026.109617_bb1530","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+\/HER2\u2212 Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb1535","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10549-017-4518-8","article-title":"Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2\u2212 advanced breast cancer in the randomized MONALEESA-2 trial","volume":"168","author":"O\u2019Shaughnessy","year":"2018","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.bioorg.2026.109617_bb1540","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.bioorg.2026.109617_bb1545","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2017.35.15_suppl.1038","article-title":"Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2\u2013), advanced breast cancer (ABC)","volume":"35","author":"Hortobagyi","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb1550","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Advanced Breast Cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb1555","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/1535-7163.MCT-15-0775","article-title":"Preclinical Characterization of G1T28: A Novel CDK4\/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression","volume":"15","author":"Bisi","year":"2016","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.bioorg.2026.109617_bb1560","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.neo.2014.05.004","article-title":"A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas","volume":"16","author":"Foulks","year":"2014","journal-title":"Neoplasia"},{"key":"10.1016\/j.bioorg.2026.109617_bb1565","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109617_bb1570","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","article-title":"The present and future of PI3K inhibitors for cancer therapy","volume":"2","author":"Castel","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.bioorg.2026.109617_bb1575","first-page":"185","article-title":"The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts, Biochimica et Biophysica Acta (BBA) - Reviews on","volume":"1870","author":"Kenna","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2026.109617_bb1580","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1016\/j.bmcl.2013.05.007","article-title":"Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation","volume":"23","author":"Furet","year":"2013","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.bioorg.2026.109617_bb1585","unstructured":"Amanda Turney, FDA approves first PI3K inhibitor for breast cancer, (n.d.). https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-pi3k-inhibitor-breast-cancer."},{"key":"10.1016\/j.bioorg.2026.109617_bb1590","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1021\/ml200156t","article-title":"Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer","volume":"2","author":"Burger","year":"2011","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/j.bioorg.2026.109617_bb1595","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1158\/2159-8290.CD-NB2015-176","article-title":"PI3K Inhibitor Improves PFS in BELLE-2 Trial","volume":"6","year":"2016","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.bioorg.2026.109617_bb1600","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","author":"Sung","year":"2021","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.bioorg.2026.109617_bb1605","unstructured":"Putting an end to cancer before it can begin, (n.d.). https:\/\/www.iarc.who.int\/wp-content\/uploads\/2024\/05\/brochure-IARC-2023-12pages-EN_2024.pdf#:\u223c:text=The%20predictions%20are%20alarming%3A%20the%20number%20of%20new,world%E2%80%99s%20people%20and%20economies%20in%20a%20precarious%20situation."},{"key":"10.1016\/j.bioorg.2026.109617_bb1610","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103407","article-title":"A global assessment of incidence trends of autoimmune diseases from 1990 to 2019 and predicted changes to 2040","volume":"22","author":"Li","year":"2023","journal-title":"Autoimmunity Reviews"},{"key":"10.1016\/j.bioorg.2026.109617_bb1615","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends in Cancer"},{"key":"10.1016\/j.bioorg.2026.109617_bb1620","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.bioorg.2026.109617_bb1625","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-023-01839-y","article-title":"Adagrasib: First Approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109617_bb1630","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1021\/acsmedchemlett.9b00196","article-title":"Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4","volume":"10","author":"Lin","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109617_bb1635","doi-asserted-by":"crossref","DOI":"10.1016\/j.slasd.2023.12.008","article-title":"Screening for molecular glues \u2013 Challenges and opportunities","volume":"29","author":"Holdgate","year":"2024","journal-title":"SLAS Discovery"},{"key":"10.1016\/j.bioorg.2026.109617_bb1640","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/molpharm.121.000306","article-title":"Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer","volume":"101","author":"Torres-Ayuso","year":"2022","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.bioorg.2026.109617_bb1645","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118055","article-title":"Global landscape of PROTAC: Perspectives from patents, drug pipelines, clinical trials, and licensing transactions","volume":"299","author":"Cai","year":"2025","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2026.109617_bb1650","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.3390\/ijms23116206","article-title":"Molecular glues: capable protein-binding small molecules that can change protein\u2013protein interactions and interactomes for the potential treatment of human cancer and neurodegenerative diseases","volume":"23","author":"Li","year":"2022","journal-title":"IJMS"},{"key":"10.1016\/j.bioorg.2026.109617_bb1655","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood.2020008676","article-title":"CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells","volume":"137","author":"Surka","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109617_bb1660","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/1535-7163.MCT-23-0747","article-title":"PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer","volume":"23","author":"Rutherford","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bioorg.2026.109617_bb1665","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.bioorg.2026.109617_bb1670","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/17425255.2023.2277758","article-title":"Tyrosine kinase inhibitors: the role of pharmacokinetics and pharmacogenetics","volume":"19","author":"Sarah","year":"2023","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"key":"10.1016\/j.bioorg.2026.109617_bb1675","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/hon.2335","article-title":"Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy: Pharmacokinetic interactions of TKIs","volume":"35","author":"Gay","year":"2017","journal-title":"Hematological Oncology"},{"key":"10.1016\/j.bioorg.2026.109617_bb1680","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40256-025-00757-6","article-title":"Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents","volume":"26","author":"Spadafora","year":"2026","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.bioorg.2026.109617_bb1685","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/ced\/llad070","article-title":"Dermatological adverse drug reactions to tyrosine kinase inhibitors: a narrative review","volume":"48","author":"Das","year":"2023","journal-title":"Clinical and Experimental Dermatology"},{"key":"10.1016\/j.bioorg.2026.109617_bb1690","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3390\/ph18070959","article-title":"Beyond the Basics: Exploring Pharmacokinetic Interactions and Safety in Tyrosine-Kinase Inhibitor Oral Therapy for Solid Tumors","volume":"18","author":"Bud\u0103u","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2026.109617_bb1695","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2020.106900","article-title":"Revisiting the hERG safety margin after 20 years of routine hERG screening","volume":"105","author":"Leishman","year":"2020","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.bioorg.2026.109617_bb1700","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112290","article-title":"hERG toxicity assessment: Useful guidelines for drug design","volume":"195","author":"Garrido","year":"2020","journal-title":"European Journal of Medicinal Chemistry"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826001537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826001537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:51:45Z","timestamp":1772891505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826001537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":340,"alternative-id":["S0045206826001537"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109617","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding landscape of kinase inhibitor research in 25 years (2001-2025) and advancements of next-generation kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109617","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109617"}}